Inicio › Linfoma de células B › Texas
Ensayos clínicos de Linfoma de células B en Texas
26 estudios sobre Linfoma de células B buscan participantes en Texas.
Ciudades en Texas
Texto oficial del estudio (inglés)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Md Anderson Cancer Center, Houston
- Texas Oncology Austin Midtown, Round Rock
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06742996A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
- University of Texas Southwestern Medical Center, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07439653A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06213311A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Texas Southwestern, Dallas
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07101328A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- M D Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT05615636A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Methodist Children's Hospital, San Antonio
ReclutandoFase 1
Edades de 0 a 18 · Todos los sexos · Actualizado el 16 sept 2026 · NCT06173518Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Austin
- Research Site, Houston
- Research Site, San Antonio
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- The University of Texas Md Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT06634589A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06564038A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06393738Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Texas Oncology - West Texas, Midland
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 31 ago 2026 · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Texas Oncology - Northeast, Tyler
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07520006Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT05826535A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Lumi Research, Kingwood
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05254743Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 12 a 80 · Todos los sexos · Actualizado el 7 ago 2026 · NCT05092451A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- St. David's South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center, Fort Worth
- MD Anderson Cancer Center, Houston
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2026 · NCT07188558A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
- The University of Texas M D Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jul 2026 · NCT05773040DALY II USA/ MB-CART2019.1 for DLBCL
- UT Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Transplant Institute, San Antonio
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT04792489Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 jul 2026 · NCT06792734Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
ReclutandoEstudio observacional
Edades de 0 a 38 · Todos los sexos · Actualizado el 4 jun 2026 · NCT06131801Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
- The University of Texas M. D. Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 may 2026 · NCT07283679The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
ReclutandoFase 1/2
Edades de 12 a 95 · Todos los sexos · Actualizado el 15 abr 2026 · NCT04329728A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- SCRI, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 nov 2025 · NCT05643742Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
- Sarah Cannon - St. David South Austin Medical Center, Austin
ReclutandoFase 1/2
Edades de 18 a 80 · Todos los sexos · Actualizado el 24 ago 2025 · NCT05607420T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 ago 2025 · NCT06343311Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
ReclutandoFase 1
Edades de 1 a 21 · Todos los sexos · Actualizado el 6 dic 2024 · NCT05476770De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.